<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108355</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-016-03F</org_study_id>
    <nct_id>NCT00108355</nct_id>
    <nct_alias>NCT00530959</nct_alias>
  </id_info>
  <brief_title>Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis</brief_title>
  <official_title>Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares a combination of two drugs that constrict blood vessels
      (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have
      cirrhosis and ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, placebo-controlled, randomized, clinical trial compares the effect of a
      combination of vasoconstrictors (octreotide plus midodrine) to albumin on the time to
      recurrence of ascites in patients with refractory ascites treated with large volume
      paracentesis. The treatment allocation ratio for the two treatment arms is 1:1 using a
      stratified random permuted block design. Subjects are patients 18-80 years old with cirrhosis
      and ascites who are stratified according to the presence or absence of renal dysfunction at
      the time of randomization. Measurements include blood pressure, weight, girth, abdominal
      ultrasound, forearm blood flow, plasma renin activity, angiotensin, and aldosterone, repeated
      during a 6 month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recurrence of Ascites.</measure>
    <time_frame>Variable depending on the patient, average 10 days</time_frame>
    <description>Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Post-paracentesis Circulatory Dysfunction (PCD)</measure>
    <time_frame>6 days after paracentesis</time_frame>
    <description>Defined as an increase in Plasma Renin Activity (PRA) by &gt;50% from baseline to a level &gt; 4 ng/mL/h at post-paracentesis day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Ascites</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Albumin (Control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasoconstrictor (Study Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed</description>
    <arm_group_label>Albumin (Control group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Saline Infusion (Albumin placebo)</intervention_name>
    <description>Intravenous saline Infusion (Albumin placebo)</description>
    <arm_group_label>Vasoconstrictor (Study Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Midodrine oral tablet at 10 mg three times a day.</description>
    <arm_group_label>Vasoconstrictor (Study Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral tablet (Midodrine placebo)</intervention_name>
    <description>Oral tablet (Midodrine placebo) three times a day</description>
    <arm_group_label>Albumin (Control group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>Octreotide LAR 20 mg intramuscular injection every 30 days</description>
    <arm_group_label>Vasoconstrictor (Study Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline injection (Octreotide LAR placebo)</intervention_name>
    <description>Saline intramuscular injection 5 cc every 30 days.</description>
    <arm_group_label>Albumin (Control group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Large Volume Paracentesis</intervention_name>
    <description>Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.</description>
    <arm_group_label>Albumin (Control group)</arm_group_label>
    <arm_group_label>Vasoconstrictor (Study Group)</arm_group_label>
    <other_name>LVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis of any etiology

          -  Age 18-80 years

          -  Moderate to severe ascites

        Exclusion Criteria:

          -  No or small ascites

          -  Severe hepatic hydrothorax

          -  Recent GI (gastrointestinal) hemorrhage

          -  Active bacterial infection

          -  Cardiac failure

          -  Organic renal disease

          -  Hepatocellular carcinoma

          -  Severe comorbidity (advanced neoplasia)

          -  Serum creatinine &gt; 3 mg/dl

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guadalupe Garcia-Tsao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Health Care System (West Haven)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Health Care System (West Haven)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Review.</citation>
    <PMID>19299324</PMID>
  </reference>
  <results_reference>
    <citation>Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81. doi: 10.1002/hep.24786.</citation>
    <PMID>22095893</PMID>
  </results_reference>
  <results_reference>
    <citation>Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grangé JD, Valla D, Lebrec D. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002 Jan;50(1):90-4.</citation>
    <PMID>11772973</PMID>
  </results_reference>
  <results_reference>
    <citation>Lata J, Marecek Z, Fejfar T, Zdenek P, Brůha R, Safka V, Hůlek P, Hejda V, Dolina J, Stehlík J, Tozzi I. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study. Hepatogastroenterology. 2007 Oct-Nov;54(79):1930-3.</citation>
    <PMID>18251131</PMID>
  </results_reference>
  <results_reference>
    <citation>Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999 Jun;29(6):1690-7.</citation>
    <PMID>10347109</PMID>
  </results_reference>
  <results_reference>
    <citation>Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia-Tsao G. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol. 2012 Oct;10(10):1169-75. doi: 10.1016/j.cgh.2012.06.027. Epub 2012 Jul 16.</citation>
    <PMID>22801062</PMID>
  </results_reference>
  <results_reference>
    <citation>Appenrodt B, Wolf A, Grünhage F, Trebicka J, Schepke M, Rabe C, Lammert F, Sauerbruch T, Heller J. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11.</citation>
    <PMID>18410283</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008 Jun;103(6):1399-405. doi: 10.1111/j.1572-0241.2008.01787.x.</citation>
    <PMID>18547224</PMID>
  </results_reference>
  <results_reference>
    <citation>Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009 Feb;29(2):169-74. doi: 10.1111/j.1478-3231.2008.01778.x. Epub 2008 May 19.</citation>
    <PMID>18492024</PMID>
  </results_reference>
  <results_reference>
    <citation>Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7.</citation>
    <PMID>16460491</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2005</study_first_submitted>
  <study_first_submitted_qc>April 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2005</study_first_posted>
  <results_first_submitted>December 11, 2013</results_first_submitted>
  <results_first_submitted_qc>February 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>albumin</keyword>
  <keyword>ascites</keyword>
  <keyword>paracentesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 2003 and June 2010, about 200 patients with cirrhosis and ascites were screened, of which, only 29 met inclusion criteria. Twenty five patients (13 control, 12 study group) were included in the analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Albumin (Control Group)</title>
          <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
        </group>
        <group group_id="P2">
          <title>Vasoconstrictors (Study Group)</title>
          <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">Two patients met inclusion criteria not randomized, one had peritonitis , other loculated ascites.</participants>
                <participants group_id="P2" count="14">Two patients met inclusion criteria not randomized, one had peritonitis, other loculated ascites.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Peritonitis at index paracentesis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loculated ascites, limiting paracentesis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albumin (Control Group)</title>
          <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
        </group>
        <group group_id="B2">
          <title>Vasoconstrictor (Treatment Group)</title>
          <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>age median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="7.5" lower_limit="51" upper_limit="61"/>
                    <measurement group_id="B2" value="60" spread="8.4" lower_limit="51" upper_limit="65"/>
                    <measurement group_id="B3" value="58" spread="8" lower_limit="51" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Recurrence of Ascites.</title>
        <description>Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group)</description>
        <time_frame>Variable depending on the patient, average 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin (Control Group)</title>
            <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
          </group>
          <group group_id="O2">
            <title>Vasoconstrictor (Treatment Group)</title>
            <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of Ascites.</title>
          <description>Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="29"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Initial estimation: median time to recurrence of ascites of 38 days in the study group and 20 days in the control group in a fixed duration of 6 months (5% type-I error (2 sided) and an 80% power). However, due to low accrual and based on randomized trials using vasoconstrictors in the prevention of PCD and a study that showed that midodrine leads to a significant improvement in effective arterial blood volume, each of which had sample sizes of 24-25 patients,we decided on a sample size of 30.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Post-paracentesis Circulatory Dysfunction (PCD)</title>
        <description>Defined as an increase in Plasma Renin Activity (PRA) by &gt;50% from baseline to a level &gt; 4 ng/mL/h at post-paracentesis day</description>
        <time_frame>6 days after paracentesis</time_frame>
        <population>Plasma Renin Activity (lab value to measure PCD) was not available for 6 patients leaving 11 patients in Albumin (control group) and 8 patients in Vasoconstrictor (Treatment group) for this outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Albumin (Control Group)</title>
            <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
          </group>
          <group group_id="O2">
            <title>Vasoconstrictor (Treatment Group)</title>
            <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Post-paracentesis Circulatory Dysfunction (PCD)</title>
          <description>Defined as an increase in Plasma Renin Activity (PRA) by &gt;50% from baseline to a level &gt; 4 ng/mL/h at post-paracentesis day</description>
          <population>Plasma Renin Activity (lab value to measure PCD) was not available for 6 patients leaving 11 patients in Albumin (control group) and 8 patients in Vasoconstrictor (Treatment group) for this outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albumin (Control Group)</title>
          <description>After LVP, patients in this group received:
Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)</description>
        </group>
        <group group_id="E2">
          <title>Vasoconstrictor (Treatment Group)</title>
          <description>After LVP, patients in this group received:
Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>GI Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difficulty to enroll patient population lead to small sample size. Midodrine not titrated for a goal increase in mean arterial pressure. Blood tests for day 6 assessment of post paracentesis circulatory dysfunction not available for all patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Guadalupe Garcia-Tsao</name_or_title>
      <organization>VA-CT Healthcare System</organization>
      <phone>203-932-5711 ext 2210</phone>
      <email>guadalupe.garcia-tsao@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

